---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-075678"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:58:21.416827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue

## Summary
- Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.
- BEACON study: 89% complete response in 240/360 mg single-dose cohorts; investigation into 240mg Q8W/240/180mg Q8W cohorts due to potential product lot variability.
- Workforce reduction of ~50% to focus on urticaria; CMO Dr. Edwin Tucker stepped down, succeeded by Dr. Daniel Adelman as interim.
- Halted non-mast cell programs (SCID, asthma ETESIAN study) to concentrate on briquilimab in CSU and CIndU.

## SEC filing metadata
- accession: 0001213900-25-075678
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/0001213900-25-075678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea0252991-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-075678
- JSON: https://secwatch.observer/filing/0001213900-25-075678.json
- Plain text: https://secwatch.observer/filing/0001213900-25-075678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.